CN1980930B - 8-[3-氨基-哌啶-1-基]-黄嘌呤,其制备及dpp-ⅳ抑制剂形式的用途 - Google Patents

8-[3-氨基-哌啶-1-基]-黄嘌呤,其制备及dpp-ⅳ抑制剂形式的用途 Download PDF

Info

Publication number
CN1980930B
CN1980930B CN2005800054231A CN200580005423A CN1980930B CN 1980930 B CN1980930 B CN 1980930B CN 2005800054231 A CN2005800054231 A CN 2005800054231A CN 200580005423 A CN200580005423 A CN 200580005423A CN 1980930 B CN1980930 B CN 1980930B
Authority
CN
China
Prior art keywords
methyl
benzyl
cyanic acid
xanthine
butyne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2005800054231A
Other languages
English (en)
Chinese (zh)
Other versions
CN1980930A (zh
Inventor
弗兰克·希梅尔斯巴赫
埃尔克·兰科普
马赛厄斯·埃克哈特
穆罕麦德·泰达扬
利奥·托马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004012921A external-priority patent/DE102004012921A1/de
Priority claimed from DE102004032263A external-priority patent/DE102004032263A1/de
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority claimed from PCT/EP2005/001427 external-priority patent/WO2005085246A1/de
Publication of CN1980930A publication Critical patent/CN1980930A/zh
Application granted granted Critical
Publication of CN1980930B publication Critical patent/CN1980930B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2005800054231A 2004-02-18 2005-02-12 8-[3-氨基-哌啶-1-基]-黄嘌呤,其制备及dpp-ⅳ抑制剂形式的用途 Active CN1980930B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE102004008112A DE102004008112A1 (de) 2004-02-18 2004-02-18 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
DE102004008112.3 2004-02-18
DE102004012921A DE102004012921A1 (de) 2004-03-17 2004-03-17 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004012921.5 2004-03-17
DE102004032263A DE102004032263A1 (de) 2004-07-03 2004-07-03 8-[3-Amino-piperidin-1yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004032263.5 2004-07-03
PCT/EP2005/001427 WO2005085246A1 (de) 2004-02-18 2005-02-12 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011100842167A Division CN102199151A (zh) 2004-02-18 2005-02-12 8-[3-氨基-哌啶-1-基]-黄嘌呤、制备及用途

Publications (2)

Publication Number Publication Date
CN1980930A CN1980930A (zh) 2007-06-13
CN1980930B true CN1980930B (zh) 2012-11-21

Family

ID=34813493

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800054231A Active CN1980930B (zh) 2004-02-18 2005-02-12 8-[3-氨基-哌啶-1-基]-黄嘌呤,其制备及dpp-ⅳ抑制剂形式的用途

Country Status (5)

Country Link
CN (1) CN1980930B (xx)
AR (1) AR115411A2 (xx)
DE (1) DE102004008112A1 (xx)
UA (1) UA87835C2 (xx)
ZA (1) ZA200604281B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
DE102008010661A1 (de) * 2008-02-22 2009-09-03 Dr. Felix Jäger und Dr. Stefan Drinkuth Laborgemeinschaft OHG Verfahren zur Herstellung von Pyridin-2-Boronsäure und Derivaten davon
CN102311448B (zh) * 2010-07-07 2014-02-19 中国科学院广州生物医药与健康研究院 噻吩并嘧啶酮类dpp-iv抑制剂
KR101985384B1 (ko) * 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
CN103450201B (zh) * 2012-05-30 2017-04-12 博瑞生物医药（苏州）股份有限公司 手性8‑（3‑氨基哌啶‑1‑基）‑黄嘌呤的制备方法
CN103709163B (zh) * 2012-09-29 2016-12-21 齐鲁制药有限公司 黄嘌呤衍生物、其制备方法及用途
CN103319483B (zh) * 2012-10-19 2016-08-03 药源药物化学（上海）有限公司 一种利拉列汀重要中间体的制备方法
CN106008507B (zh) * 2013-01-23 2017-11-28 成都苑东生物制药股份有限公司 黄嘌呤衍生物
TWI682931B (zh) * 2015-05-29 2020-01-21 大陸商江蘇天士力帝益藥業有限公司 黃嘌呤衍生物、其藥物組成物、其製劑以及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068420A1 (de) * 2001-02-24 2002-09-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthinderivate, deren herstellung und deren verwendung als arzneimittel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068420A1 (de) * 2001-02-24 2002-09-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthinderivate, deren herstellung und deren verwendung als arzneimittel

Also Published As

Publication number Publication date
ZA200604281B (en) 2007-10-31
CN1980930A (zh) 2007-06-13
UA87835C2 (xx) 2009-08-25
DE102004008112A1 (de) 2005-09-01
AR115411A2 (es) 2021-01-13

Similar Documents

Publication Publication Date Title
CN102199151A (zh) 8-[3-氨基-哌啶-1-基]-黄嘌呤、制备及用途
CN1980930B (zh) 8-[3-氨基-哌啶-1-基]-黄嘌呤,其制备及dpp-ⅳ抑制剂形式的用途
EP1720875B1 (de) 8- [3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel
CN101503408B (zh) 8-[3-氨基-哌啶-1-基]-黄嘌呤化合物
JP2007522251A6 (ja) ８−［３−アミノ−ピペリジン−１−イル］−キサンチン、その製造及びそのｄｐｐ−ｉｖインヒビターの形態での使用
EP1709049B1 (de) Bicyclische imidazolverbindungen, deren herstellung und deren verwendung als arzneimittel
KR101446692B1 (ko) １－［（３－시아노－피리딘－2－일）메틸］－3－메틸－7－（２－부틴－１－일）－８－（３－아미노－피페리딘－１－일）－크산틴의 하이드로클로라이드 및 수화물, 이의 제조법 및 의약으로서의 이의 용도
US7501426B2 (en) 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
JP2008512412A (ja) 新規８−（３−アミノ−ピペリジン−１−イル）−７−（ブタ−２−イニル）−キサンチン類、それらの製造方法及び医薬組成物としてのそれらの使用
JP2007523114A6 (ja) ８−［３−アミノ−ピペリジン−１−イル］−キサンチン、それらの製造及び医薬組成物としてのそれらの使用
JP2008513390A (ja) 新規３−メチル−７−ブチニル−キサンチン、その製造方法及び医薬組成物としての使用
JP2007531780A (ja) 新規な２−アミノ−イミダゾ［４，５−ｄ］ピリダジン−４−オン及び２−アミノ−イミダゾ［４，５−ｃ］ピリダジン−４−オン、その製法及び医薬としての使用
CN102964347A (zh) 8-[3-氨基-哌啶-1-基]-黄嘌呤化合物，其制备方法及作为药物制剂的用途
JP2006512311A (ja) キサンチン誘導体、その製法及びその医薬組成物としての使用
DE10359098A1 (de) Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
ES2348553T3 (es) Compuestos bicíclicos de imidazol, su preparación y uso como medicamentos.
MXPA06009289A (en) 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a dpp inhibitor
AU2012202850A1 (en) 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1103402

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1103402

Country of ref document: HK